Margarita Fallena, MD
Rheumatology · Dallas, TXNPI 1760686737
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 25.2% of the total.
Across 311 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$894
- Novartis$771
- Pfizer$731
- GSK$317
- UCB, Inc.$259
- plus $1K from 20 others
Across 49 payments — averaging $9887.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$299K
- Amgen$103K
- UCB SA$64K
- GSK$18K
What the payments were for
- Food & beverage$5,455100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,374 |
| Amgen(2 entities) | 50 | $894 |
| Novartis | 44 | $771 |
| Pfizer | 61 | $731 |
| GSK | 18 | $317 |
| UCB, Inc. | 11 | $259 |
| Johnson & Johnson(2 entities) | 20 | $244 |
| ANI Pharmaceuticals, Inc. | 4 | $108 |
| Lilly USA, LLC | 5 | $99 |
| Boehringer Ingelheim | 4 | $86 |
| Fresenius Kabi USA, LLC | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Genentech USA, Inc. | 3 | $56 |
| AstraZeneca | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 3 | $46 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Hospira, Inc. | 3 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Octapharma USA, Inc. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Zimmer Biomet | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,463 in reported general payments places this provider in the 55th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 32 | $236,845 |
| Humira(Cf) PenAdalimumab | 20 | $126,893 |
| Enbrel SureclickEtanercept | 14 | $97,614 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $91,130 |
| Hydroxychloroquine Sulfate | 268 | $6,452 |
| MethotrexateMethotrexate Sodium | 174 | $2,588 |
| Leflunomide | 71 | $2,495 |
| Duloxetine Hcl | 144 | $2,264 |
| Mycophenolate Mofetil | 17 | $2,051 |
| Pilocarpine Hcl | 25 | $1,803 |
| Prednisone | 221 | $1,665 |
| Celecoxib | 54 | $1,061 |
| Cevimeline Hcl | 13 | $1,041 |
| Alendronate Sodium | 73 | $1,014 |
| Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein | 11 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,374 | $236,84532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- John CushDallas$3.7M
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
- Stanley CohenDallas$318K
- Joanna GeslaniDallas$242K
- Sharad LakhanpalDallas$229K
- Iftikhar ChowdhryDallas$226K
- Srilatha KothandaramanDallas$140K
- Leyka BarbosaDallas$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.